Table 3.
SN, SP, PPV, and NPV of CA125, HE4, ROMA, and CPH-I in differentiating BOT I+II from EOC I+II group stratification by different menopausal statuses.
| Menopausal status | SN (%) | SP (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|
| All | ||||
| HE4 | 65.74 | 84.03 | 75.53 | 76.58 |
| CA125 | 55.56 | 81.25 | 68.97 | 70.91 |
| ROMA | 62.96 | 88.19 | 46.45 | 75.61 |
| CPH-I | 78.7 | 74.31 | 69.70 | 82.30 |
| Pre-M | ||||
| HE4 | 73.77 | 66.39 | 64.00 | 78.20 |
| CA125 | 54.1 | 82.79 | 61.11 | 78.29 |
| ROMA | 78.69 | 64.75 | 63.23 | 85.71 |
| CPH-I | 70.49 | 78.69 | 62.30 | 84.20 |
| Post-M | ||||
| HE4 | 70.21 | 90.91 | 88.64 | 68.00 |
| CA125 | 76.6 | 63.64 | 81.82 | 44.44 |
| ROMA | 82.98 | 68.18 | 73.21 | 53.85 |
| CPH-I | 85.11 | 68.18 | 85.10 | 68.20 |
Abbreviations: SN = sensitivity; SP = specificity; PPV = positive predictive value; NPV = negative predictive value; Pre-M = premenopausal; Post-M = postmenopausal; BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.